Seroquel XR Articles
US Court upholds AstraZeneca Seroquel XR patent
30 March 2012
AstraZeneca sues US FDA over Seroquel decision
13 March 2012
AstraZeneca Seroquel petitions denied by US FDA
9 March 2012
Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients
30 October 2011
AstraZeneca in two more Seroquel XR patent settlements; Actavis outlines South America aims
6 October 2011
AstraZeneca in patent settlement deal with Handa over Seroquel XR
30 September 2011
First-line use of Abilify more than doubles over past year for newly-diagnosed patients with bipolar disorder
19 November 2010
Europe’s CHMP updates on pandemic vaccines, backs use extensions for Reyataz and RoActemra, concludes Seroquel XR arbitration
26 April 2010
Safety and clinical benefits of AstraZeneca’s Seroquel XR need to be demonstrated for its approval as an MDD monotherapy, says DR
28 January 2010
US FDA approves AstraZeneca’s Seroquel XR for add-on treatment of MMD and standard drug for pediatric use
4 December 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
AstraZeneca’s Seroquel gets EU approval for bipolar recurrence
30 September 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Seroquel unsafe for new indications; panel
9 April 2009
AZ gets FDA complete response on Seroquel in GAD
9 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
AZ awaits news of new indications for Seroquel
2 March 2009
FDA asks for more info on Seroquel in MDD
12 January 2009
FDA warns AZ of off-label promotion case
15 December 2008
Biovail files ANDA for quetiapine
8 December 2008
FDA nod for Seroquel XR in bipolar disorder
20 October 2008
AZ reports good results for Seroquel XR in GAD
8 September 2008
AstraZeneca submits EU MAA for Seroquel XR in MDD
16 June 2008
Seroquel XR fares well in MDD and GAD
19 May 2008
AZ submits sNDA for Seroquel to treat GAD
19 May 2008
Seroquel XR filed with FDA for MDD
10 March 2008
AstraZeneca files for new Seroquel indication in EU
18 February 2008
AZ files Seroquel XR for biopolar mania and depression
14 January 2008
Seroquel impresses in MDD and GAD studies
10 December 2007
FDA clears Seroquel XR as maintenance therapy
26 November 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Dutch approval for AstraZeneca's once-daily Seroquel XR
3 September 2007
Showing 1-42 of 42 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
